Table 2.
Tumor associated proteins in EVs/exosomes derived from human tumor cell linesa
Not cell-type specificb | EV cell source | Biological effects | Reference |
Tetraspanins: CD9, CD63, CD81 | Normal or tumor cells | Exosome sorting | 134, 135 |
Heat shock proteins: Hsp70, HSP90 | Various tumor cells | Exosome antigenicity | 54,136 |
Biogenesis associated: TSG-101, ALIX | Normal or tumor cells | Exosome formation | 26, 136 |
Membrane transport: anexins, flotellin, caveolin-1, Rab GTPase | Normal or tumor cells | Exosome release | 137, 138, 139 |
Immune cell apoptosis FasL, TRAIL, galectin-9 | Various tumor cells | Immune suppression by exosomes | 32, 34, 35 124, 140 |
Cancer cell-associatedc | Tumor type | Pro-tumor effects | Reference |
Amplified oncogenes (K-ras mut) | CRC | Oncogene transfer | 40–44 |
EGFRVIII mut | GBM | Growth | 141, 142 |
IDH1, IDH2 mut | GBM, meduloblastoma | Growth, invasion | 141, 143, 144 |
Amphiregulin | BRCA, CRC | Growth, invasion | 145 |
Survivin | Inhibits apoptosis | 146 | |
GD2 ganglioside | NB | Immune suppression | 146 |
FGF-2 | Meduloblastoma | Growth | 143 |
LMP-1 | NPC | Signal Transduction | 148 |
MUC-1 | BRCA | Growth, invasion | 149 |
Del-1 | Mesothelioma | Angiogenesis | 143 |
EpCAM | CRC | Growth, invasion | 96 |
TGF-β | GBM, BRCA | Immune Suppression | 142 |
Mesothelioma | Stroma remodeling | 61, 62 | |
VEGF, TIMP 1, MMP-9 | GBM | Growth, invasion, stroma | 44 |
Abbreviations: GBM, glioblastoma multiforme; med bl, medulloblastoma; BRCA, breast carcinoma; NB, neuroblastoma; NPC, nasopharyngeal carcinoma; CRC, colorectal cancer.
EVs were isolated from supernatants of tumor cell lines by various methods, without discrimination of larger EVs from smaller exosomes.
The proteins listed are present in EVs isolated from tumor cells at higher levels compared to those observed in EVs obtained from normal cells.